How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells
In this talk, Dr. Dominika Nackiewicz introduces how STEMCELL Technologies can help optimize your T cell cultures with robust, high-performance products and expert support. You will learn how to generate high yields of functional T cells for cell therapy development and manufacturing using the new GMP ImmunoCult™ medium and activators. She will also discuss efficient gene editing strategies using the new CellPore™ Transfection System and solutions for T cell generation from pluripotent stem cells or hematopoietic stem and progenitor cells.
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells?
In this webinar, Dr. Julian J. Lum discusses key factors to consider when choosing metabolic assays and how they can be used to assess cell function. Additionally, he discusses the metabolic characteristics of different commercially available cell culture media formulations as well as the importance of assessing the array of media products and their impact on metabolism.
Next-Generation Cell Isolation Solutions for T Cell Therapy Research
Join this talk, presented by Dr. Amanda Durkin and Q&A guest Dr. Frann Antignano, to learn about STEMCELL’s cell isolation solutions for fast and easy T cell isolation. This presentation will also focus on large-scale research strategies by introducing our new mobilized leukopaks and feature the Easy 250 EasySep™ Magnet—a scalable and efficient system for manual column-free isolation.
Combining CAR T Cells with STING Agonists to Fight Solid Tumors
In this webinar, Dr. Uslu describes how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.
Implementing the Colony-Forming Unit (CFU) Assay As a Potency Assay for Hematopoietic Cell Therapy Products
Assessing the functional potency of cells for use in cell therapy research presents unique challenges. For hematopoietic stem and progenitor cells (HSPCs) in particular, potency can be measured in vitro by assessing the ability of these cells to differentiate into progenitor cells using the colony-forming unit (CFU) assay. Validating the CFU assay as a potency assay requires demonstrating its specificity, accuracy, precision, linearity, and reproducibility. Once validated, the CFU assay can assess the quality and consistency of prospective hematopoietic cell therapy products (HCTPs) at multiple stages of the processing and manufacturing workflow.
Join Dr. Colin Hammond and learn about the regulatory guidance around the potency testing of HCTPs and how to validate the CFU assay as a potency assay that can be integrated into cell therapy manufacturing workflows.
EasySep™小鼠TIL（CD45）正选试剂盒
How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells In this talk, Dr. Dominika Nackiewicz introduces how STEMCELL Technologies can help optimize your T cell cultures with robust, high-performance products and expert support. You will learn how to generate high yields of functional T cells for cell therapy development and manufacturing using the new GMP ImmunoCult™ medium and activators. She will also discuss efficient gene editing strategies using the new CellPore™ Transfection System and solutions for T cell generation from pluripotent stem cells or hematopoietic stem and progenitor cells.
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells? In this webinar, Dr. Julian J. Lum discusses key factors to consider when choosing metabolic assays and how they can be used to assess cell function. Additionally, he discusses the metabolic characteristics of different commercially available cell culture media formulations as well as the importance of assessing the array of media products and their impact on metabolism.
Next-Generation Cell Isolation Solutions for T Cell Therapy Research Join this talk, presented by Dr. Amanda Durkin and Q&A guest Dr. Frann Antignano, to learn about STEMCELL’s cell isolation solutions for fast and easy T cell isolation. This presentation will also focus on large-scale research strategies by introducing our new mobilized leukopaks and feature the Easy 250 EasySep™ Magnet—a scalable and efficient system for manual column-free isolation.
Combining CAR T Cells with STING Agonists to Fight Solid Tumors In this webinar, Dr. Uslu describes how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.
Implementing the Colony-Forming Unit (CFU) Assay As a Potency Assay for Hematopoietic Cell Therapy Products Assessing the functional potency of cells for use in cell therapy research presents unique challenges. For hematopoietic stem and progenitor cells (HSPCs) in particular, potency can be measured in vitro by assessing the ability of these cells to differentiate into progenitor cells using the colony-forming unit (CFU) assay. Validating the CFU assay as a potency assay requires demonstrating its specificity, accuracy, precision, linearity, and reproducibility. Once validated, the CFU assay can assess the quality and consistency of prospective hematopoietic cell therapy products (HCTPs) at multiple stages of the processing and manufacturing workflow.
